Editorial: eHealth and personalized medicine in mental health and neurodevelopmental disorders: digital innovation for diagnosis, care, and clinical management.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are incretin-based therapies originally developed for type 2 diabetes mellitus and, more recently, obesity (, ). Agents such as semaglutide, liraglutide, dulaglutide, and exenatide enhance glucose-dependent insulin secretion, suppress glucagon release, and promote satiety through central appetite regulation (). Beyond their metabolic indications, accumulating evidence has linked GLP-1 RA use to effects on psychiatric outcomes including depression, anxiety, substance use disorders (SUDs), eating disorders, suicidality, and cognitive function (). GLP-1 receptors are expressed throughout the central nervous system, including the mesolimbic reward pathway, hippocampus, and prefrontal cortex, providing a plausible neurobiological basis for these effects (, ). Recent large-scale studies have supported these observations: Xie et al. () reported reduced risks of SUDs, psychotic disorders, and neurocognitive disorders among 215, 970 GLP-1 RA users; a Swedish national cohort study found a 42% reduced risk of worsening psychiatric outcomes with semaglutide specifically in individuals with depression or anxiety (); and a meta-analysis of 80 randomised controlled trials characterised the psychiatric adverse event profile of these agents (). As this literature has grown rapidly, narrative and systematic reviews have provided useful syntheses of clinical evidence (, ), but these are designed to evaluate treatment effects rather than characterise the research landscape. Bibliometric analysis offers a complementary approach by quantifying publication trends, identifying intellectual and social structures, and mapping collaboration networks across an entire field (, ). Through techniques such as keyword co-occurrence analysis, thematic mapping, and co-authorship network analysis, bibliometric methods can reveal emerging research frontiers and structural gaps that are not visible from individual reviews. Unlike a conventional systematic review, the present study synthesises the characteristics of the literature itself rather than the clinical effects reported within it. Previous bibliometric analyses of GLP-1 RA research have focused on semaglutide broadly (), cardiovascular disease (, ), obesity management (), and tirzepatide pharmacology (). None has focused on psychiatric or mental health outcomes, a notable gap given the rapidly growing clinical and regulatory interest in the neuropsychiatric effects of this drug class and the interdisciplinary nature of the field, which spans endocrinology, psychiatry, neuroscience, pharmacology, and addiction medicine.